KaliVir Immunotherapeutics raises $14m Series A
Company K Partners, SV Investment and other investors participated in the financing.
KaliVir Immunotherapeutics raised $14 million in Series A financing on August 19. Participants included Company K Partners, SV Investment, Flexus Partners, Nextrans and Quad Investment Management. The company develops oncolytic immunotherapies for advanced solid tumors.